{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T18:05:27Z","timestamp":1777572327525,"version":"3.51.4"},"reference-count":27,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2016,12,7]],"date-time":"2016-12-07T00:00:00Z","timestamp":1481068800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["HHSN272200700035C"],"award-info":[{"award-number":["HHSN272200700035C"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Translational Sci"],"published-print":{"date-parts":[[2017,1]]},"abstract":"<jats:p>Obiltoxaximab, a monoclonal antibody against protective antigen (PA), is approved for treatment of inhalational anthrax under the US Food and Drug Administration's (FDA) Animal Rule. The human dose was selected and justified by comparing observed obiltoxaximab exposures in healthy and infected New Zealand White rabbits and cynomolgus macaques to observed exposures in healthy humans, to simulated exposures in healthy and infected humans, and to serum PA levels in infected animals. In humans, at 16 mg\/kg intravenous, obiltoxaximab AUC was &gt;2 times that in animals, while maximum serum concentrations were comparable to those in animals and were maintained in excess of the concentration required for PA neutralization in infected animals for 2\u20133 weeks. Obiltoxaximab 16 mg\/kg in humans provided exposure beyond that of 16 mg\/kg in animals, ensuring a sufficient duration of PA neutralization to allow for adaptive immunity development. Our approach to dose translation may be applicable to other agents being developed under the Animal Rule.<\/jats:p>","DOI":"10.1111\/cts.12433","type":"journal-article","created":{"date-parts":[[2016,12,7]],"date-time":"2016-12-07T12:48:45Z","timestamp":1481114925000},"page":"12-19","source":"Crossref","is-referenced-by-count":21,"title":["Animal\u2010to\u2010Human Dose Translation of Obiltoxaximab for Treatment of Inhalational Anthrax Under the US FDA Animal Rule"],"prefix":"10.1111","volume":"10","author":[{"given":"CF","family":"Nagy","sequence":"first","affiliation":[{"name":"Department of Clinical Operations Elusys Therapeutics, Inc Pine Brook  New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Mondick","sequence":"additional","affiliation":[{"name":"Metrum Research Group LLC  Tariffville Connecticut USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N","family":"Serbina","sequence":"additional","affiliation":[{"name":"Department of Research and Nonclinical Development, Elusys Therapeutics, Inc Pine Brook  New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"LS","family":"Casey","sequence":"additional","affiliation":[{"name":"Department of Research and Nonclinical Development, Elusys Therapeutics, Inc Pine Brook  New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SE","family":"Carpenter","sequence":"additional","affiliation":[{"name":"Department of Research and Nonclinical Development, Elusys Therapeutics, Inc Pine Brook  New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"French","sequence":"additional","affiliation":[{"name":"Metrum Research Group LLC  Tariffville Connecticut USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Guttendorf","sequence":"additional","affiliation":[{"name":"Aclairo Pharmaceutical Development Group Inc  Vienna Virginia USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,12,7]]},"reference":[{"key":"e_1_2_9_1_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199909093411107"},{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.micro.55.1.647"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.287.17.2236"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.3201\/eid2002.130687"},{"key":"e_1_2_9_5_1","unstructured":"National Institute of Allergy and Infectious Diseases. NIAID Category A B and C Priority Pathogens.2016(cited January 28 2016); Available from:https:\/\/www.niaid.nih.gov\/topics\/biodefenserelated\/biodefense\/pages\/cata.aspx"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.3201\/eid0706.010604"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.3390\/toxins3111433"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.73.2.795-802.2005"},{"key":"e_1_2_9_9_1","unstructured":"FDA Product Development Under the Animal Rule: Draft Guidance for Industry. Silver Spring MD: US Department of Health and Human Servies Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluaiton and Research (CBER) (2009)."},{"key":"e_1_2_9_10_1","unstructured":"FDA Product Development Under the Animal Rule: Guidance for Industry. Silver Spring MD: US Department of Health and Human Servies Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluaiton and Research (CBER) (2015)."},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2016.07.170"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00288-12"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.LAB.0000080599.43791.01"},{"key":"e_1_2_9_14_1","first-page":"982","article-title":"The pathology of experimental anthrax in rabbits exposed by inhalation and subcutaneous inoculation","volume":"122","author":"Zaucha G.M.","year":"1998","journal-title":"Arch. Pathol. Lab. Med."},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00972-16"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt0602-597"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M301154200"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.74.1.394-398.2006"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01689-10"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.00792-06"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00292-12"},{"key":"e_1_2_9_22_1","volume-title":"Committee for the Update of the Guide for the Care and Use of Laboratory Animals","author":"National Research Council (US)","year":"2011"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01102-16"},{"key":"e_1_2_9_24_1","unstructured":"Anthim.Package insert. Elusys Therapeutics Inc. 25 Riverside Drive Pine Brook NJ (2016). Available from:http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/125509lbl.pdf"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1086\/423937"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1086\/512372"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.3390\/toxins5010120"}],"container-title":["Clinical and Translational Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fcts.12433","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.12433","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T05:48:09Z","timestamp":1696398489000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1111\/cts.12433"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,7]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["10.1111\/cts.12433"],"URL":"https:\/\/doi.org\/10.1111\/cts.12433","archive":["Portico"],"relation":{},"ISSN":["1752-8054","1752-8062"],"issn-type":[{"value":"1752-8054","type":"print"},{"value":"1752-8062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,7]]}}}